Lynparza fails a PhIII test in colorectal cancer, cutting off big R&D avenue for Merck and AstraZeneca
As AstraZeneca and Merck look to continue building out their Lynparza franchise, one cancer type is proving too tough a nut to crack.
The Big Pharma partners reported Tuesday morning that a Phase III trial evaluating Lynparza in colorectal cancer as both a monotherapy and in combination with Avastin was stopped early due to futility. The move comes after the data monitoring committee reviewed data for a planned interim analysis. Both drug arms will be discontinued, the companies said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.